Costet P - Search Results

1

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.

Vergès B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B. Vergès B, et al. Among authors: costet p. Atherosclerosis. 2011 Nov;219(1):342-8. doi: 10.1016/j.atherosclerosis.2011.07.098. Epub 2011 Jul 26. Atherosclerosis. 2011. PMID: 21889145

2

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.

Costet P, Hoffmann MM, Cariou B, Guyomarc'h Delasalle B, Konrad T, Winkler K. Costet P, et al. Atherosclerosis. 2010 Sep;212(1):246-51. doi: 10.1016/j.atherosclerosis.2010.05.027. Epub 2010 May 25. Atherosclerosis. 2010. PMID: 20619837 Clinical Trial.

3

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.

Costet P, Krempf M, Cariou B. Costet P, et al. Trends Biochem Sci. 2008 Sep;33(9):426-34. doi: 10.1016/j.tibs.2008.06.005. Epub 2008 Jul 30. Trends Biochem Sci. 2008. PMID: 18672372 Review.

4

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients.

Cariou B, Le Bras M, Langhi C, Le May C, Guyomarc'h-Delasalle B, Krempf M, Costet P. Cariou B, et al. Among authors: costet p. Atherosclerosis. 2010 Aug;211(2):700-2. doi: 10.1016/j.atherosclerosis.2010.04.015. Epub 2010 Apr 20. Atherosclerosis. 2010. PMID: 20452593

5

Clinical aspects of PCSK9.

Cariou B, Le May C, Costet P. Cariou B, et al. Among authors: costet p. Atherosclerosis. 2011 Jun;216(2):258-65. doi: 10.1016/j.atherosclerosis.2011.04.018. Epub 2011 Apr 22. Atherosclerosis. 2011. PMID: 21596380 Review.

6

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.

Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M. Costet P, et al. J Biol Chem. 2006 Mar 10;281(10):6211-8. doi: 10.1074/jbc.M508582200. Epub 2006 Jan 6. J Biol Chem. 2006. PMID: 16407292 Free article.

7

PCSK9: a promising therapeutic target for dyslipidemias?

Lambert G, Krempf M, Costet P. Lambert G, et al. Among authors: costet p. Trends Endocrinol Metab. 2006 Apr;17(3):79-81. doi: 10.1016/j.tem.2006.02.001. Epub 2006 Feb 17. Trends Endocrinol Metab. 2006. PMID: 16487721

8

Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.

Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zaïr Y, Nguyen P, Krempf M, Cariou B, Costet P. Kourimate S, et al. Among authors: costet p. J Biol Chem. 2008 Apr 11;283(15):9666-73. doi: 10.1074/jbc.M705831200. Epub 2008 Feb 3. J Biol Chem. 2008. PMID: 18245819 Free article.

9

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.

Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B. Langhi C, et al. Among authors: costet p. FEBS Lett. 2008 Mar 19;582(6):949-55. doi: 10.1016/j.febslet.2008.02.038. Epub 2008 Feb 25. FEBS Lett. 2008. PMID: 18298956 Free article.

10

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia.

Le May C, Kourimate S, Langhi C, Chétiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P. Le May C, et al. Among authors: costet p. Arterioscler Thromb Vasc Biol. 2009 May;29(5):684-90. doi: 10.1161/ATVBAHA.108.181586. Epub 2009 Mar 5. Arterioscler Thromb Vasc Biol. 2009. PMID: 19265033

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters